Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Notes announcement from Inhibrx Inc and Sanofi SA that both companies have agreed Sanofi will acquires all assets and liabilities associated with INBRX-101. INBRX-101 is an optimised recombinant alpha-1 antitrypsin augmentation therapy, currently undergoing a residential trial treating patients with alpha-11 antitrypsin deficiency or AATD. INBRX-101 incorporates "a novel enhanced formulation" developed by Arecor using its patented Arestat technology. Arecor and Inhibrx entered a license agreement in December 2020.

Arecor Chief Executive Officer Sarah Howell says: "Following on from the recent commercialisation of AT220, which is now royalty-bearing for Arecor, the acquisition of Inhibrx for INBRX-101 by Sanofi, announced today, is a further endorsement of the Arestat platform.

"Sanofi is a global pharmaceutical leader with a 30-year heritage in rare diseases and this acquisition highlights both the value of this novel therapy for patients and its future commercial potential. We believe they are well placed to complete the late-stage development of this novel medicine and, ultimately, bring it to patients in need."

Current stock price: 167.77 pence

12-month change: down 27%

By Emma Curzon, Alliance News reporter

Comments and questions to

Copyright 2024 Alliance News Ltd. All Rights Reserved.